• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Canada's Biovail to buy Valeant

Article

Mississauga, Ontario - Biovail, Canada’s largest pharmaceutical firm, plans to purchase Valeant Pharmaceuticals, based in Aliso Viejo, Calif., for about $3.3 billion, according to in-Pharmatechnologist.com.

Mississauga, Ontario - Biovail, Canada’s largest pharmaceutical firm, plans to purchase Valeant Pharmaceuticals, based in Aliso Viejo, Calif., for about $3.3 billion, according to in-Pharmatechnologist.com.

The transaction, which awaits shareholder approval, will result in a new combined entity, Valeant Pharmaceuticals International, to be based in Mississauga.

Market analysts say the merger would create a company with estimated revenues of $900 million a year.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.